⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16600475 | 0.98 | CHRNB2 (0.55) | — | |
| Hydrochloric Acid SCHEMBL18230043 | 0.98 | CHRNB2 (0.55) | — | |
| Bromide SCHEMBL8691876 | 0.98 | CHRNB2 (0.55) | — | |
| Bromide SCHEMBL8686784 | 0.98 | CHRNB2 (0.55) | — | |
| SCHEMBL3414893 | 0.87 | SIGMAR1 (0.54) | — | |
| SCHEMBL7019778 | 0.85 | SIGMAR1 (0.57) | — | |
| SCHEMBL10205529 | 0.84 | SIGMAR1 (0.55) | — | |
| SCHEMBL549069 | 0.82 | — | — | |
| SCHEMBL29844361 | 0.82 | — | — | |
| SCHEMBL21707011 | 0.81 | CHRNB2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143178-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | claimed |
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | claimed |
| CN-1402720-A | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | claimed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719411-A2 | QUINOLINEAMINE AND PYRIDOQUINOLINE ANTIDEGRADANT COMPOUNDS AND USES THEREOF | Flexsys IP Holdings, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260076973-A1 | Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses | Viradem, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4704835-A2 | ANTIDEGRADANT BIS(DIHYDRO AND TETRAHYDROQUINOLINE) COMPOUNDS AND USES THEREOF | Flexsys IP Holdings, LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570679-B2 | STAT3 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4687882-A2 | 6-AMINOQUINOLINE ANTIDEGRADANTS | Flexsys IP Holdings, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| CN-1402720-A | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |